Investors Get Selective As China Biotech Funding Rebounds

Oversee returnee-founded Chinese biotech start-ups Nuwacell and Arnatar secure $14m in series A and seed rounds respectively, while four other major deals backed by private equity and venture capital firms raise a combined $116m.

funding
Venture capital, private equity investors turn to overseas returnees with new initiatives • Source: Shutterstock

More from China

More from Focus On Asia